세계의 ANCA 관련 혈관염 시장 보고서(2025년)

Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis is a rare autoimmune disorder marked by inflammation and damage to small and medium-sized blood vessels, primarily affecting organs such as the kidneys, lungs, and respiratory tract. If left untreated, it can lead to serious complications. This condition intersects with nephrology, pulmonology, and rheumatology, and requires a multidisciplinary approach involving immunosuppressive therapies, corticosteroids, and advanced treatment strategies to prevent organ failure and enhance long-term outcomes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of ANCA-associated vasculitis include granulomatosis with polyangiitis (GPA or Wegener's), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss), and other variants. Granulomatosis with polyangiitis (GPA), previously known as Wegener's granulomatosis, is a systemic form of AAV characterized by granuloma formation and inflammation in small to medium-sized vessels, often impacting the respiratory system, kidneys, and other organs. Treatment options include immunosuppressants, corticosteroids, biologics, and other therapies, with diagnosis supported by blood tests, biopsies, imaging studies, and additional diagnostic tools.

The ANCA associated vasculitis market research report is one of a series of new reports from The Business Research Company that provides ANCA associated vasculitis market statistics, including ANCA associated vasculitis industry global market size, regional shares, competitors with a ANCA associated vasculitis market share, detailed ANCA associated vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the ANCA associated vasculitis industry. This ANCA associated vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market size has grown strongly in recent years. It will grow from $0.57 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth observed during the historic period can be attributed to increased healthcare expenditure, rising disposable income, a stronger focus on patient-centered care, an expanding middle-class population, greater adoption of telemedicine, and a growing geriatric population.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market size is expected to see strong growth in the next few years. It will grow to $0.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth projected during the forecast period can be attributed to expanding research and clinical trials, increased research and development activities, a rising incidence of autoimmune diseases, growing cases of immune system dysfunction, and a higher prevalence of various associated risk factors. Key trends expected during this period include the rise of personalized medicine, strategic collaborations, advancements in diagnostic testing, increased adoption of telemedicine, and the development of combination therapies.

The increasing prevalence of autoimmune diseases is anticipated to propel the growth of the ANCA-associated vasculitis market in the coming years. Autoimmune diseases occur when the immune system erroneously targets the body's own healthy cells and tissues, mistaking them for harmful invaders such as bacteria or viruses. The rise in these conditions is linked to environmental factors and modern lifestyle habits, with greater exposure to infections and pollutants significantly contributing by disturbing immune tolerance and triggering abnormal immune responses. ANCA-associated vasculitis positively influences advancements in autoimmune disease research and treatment by promoting the development of targeted immunosuppressive therapies, boosting early diagnostic capabilities, and refining overall disease management approaches. These advancements ultimately lead to improved patient outcomes and a deeper insight into immune system regulation. For example, in September 2023, the Impact of IBD Report 2023, published by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre a Canada-based organization dedicated to improving the lives of those with Crohn's disease and ulcerative colitis stated that in 2023, IBD affected 825 per 100,000 Canadians, totaling over 320,000 individuals. With an anticipated annual growth rate of 2.44% in prevalence, it is estimated that by 2035, around 470,000 people, or 1.1% of the Canadian population, will be living with IBD. Consequently, the growing occurrence of autoimmune diseases will support the expansion of the ANCA-associated vasculitis market.

Leading companies in the ANCA-associated vasculitis market are prioritizing the development of innovative solutions such as targeted therapies to offer new treatment options for patients with this rare and severe disease. Targeted therapies for ANCA-associated vasculitis utilize specialized biologic agents that specifically inhibit immune components responsible for inflammation and blood vessel damage, thereby limiting disease advancement and reducing the side effects linked to conventional treatments. For instance, in February 2023, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a Switzerland-based pharmaceutical firm, received approval from the Therapeutic Goods Administration (TGA) an Australian government regulatory body for Tavneos (avacopan) to treat ANCA-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide-based regimens. This approval is a significant milestone, as Tavneos is the first targeted treatment specifically developed for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. The therapy works by selectively blocking the complement C5a receptor (C5aR1), helping to manage inflammation and disease progression while reducing dependence on high-dose glucocorticoids (steroids), which are known for their serious long-term side effects.

In March 2024, Q32 Bio Inc., a U.S.-based clinical-stage biotechnology company, merged with Homology Medicines, Inc. for an undisclosed sum. This merger enables Q32 Bio to enhance its standing as a publicly traded biotech firm by securing resources to further develop key biologic therapies such as bempikibart for autoimmune conditions including atopic dermatitis and alopecia areata, and ADX-097 for complement-mediated disorders, with a Phase 2 trial targeting ANCA-associated vasculitis scheduled for early 2025. Homology Medicines Inc. is a U.S.-based clinical-stage genetic medicines company specializing in treatments for rare diseases.

Major players in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Fresenius Medical Care (FMS), Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Biogen Inc., Quest Diagnostics Inc, Csl Behring AG, ARUP Laboratories, Sebia Inc., Exagen Inc., Argenx SE, Arkana Laboratories, Alentis Therapeutics AG, Hansa Biopharma AB, InflaRx NV.

North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, disease management, and patient counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market also includes sales of biologic therapies, plasma exchange equipment, diagnostic test kits, targeted oral therapies, and monoclonal antibodies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antineutrophil cytoplasmic antibody (anca) associated vasculitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antineutrophil cytoplasmic antibody (anca) associated vasculitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antineutrophil cytoplasmic antibody (anca) associated vasculitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Granulomatosis With Polyangiitis (GPA Or Wegener's); Microscopic Polyangiitis (MPA); Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss); Other Types
• 2) By Treatment: Immunosuppressants; Corticosteroids; Biologics; Other Treatments
• 3) By Diagnosis: Blood Tests; Biopsy; Imaging; Other Diagnosis
• Subsegments:
• 1) By Granulomatosis With Polyangiitis (GPA or Wegener's): Limited Granulomatosis With Polyangiitis; Severe Granulomatosis With Polyangiitis; Refractory Granulomatosis With Polyangiitis
• 2) By Microscopic Polyangiitis (MPA): Renal Microscopic Polyangiitis; Pulmonary Microscopic Polyangiitis; Neurological Microscopic Polyangiitis
• 3) By Eosinophilic Granulomatosis With Polyangiitis (EGPA or Churg-Strauss): Cardiac Eosinophilic Granulomatosis With Polyangiitis; Pulmonary Eosinophilic Granulomatosis With Polyangiitis; Neurological Eosinophilic Granulomatosis With Polyangiitis
• 4) By Other Types: Drug-Induced ANCA-Associated Vasculitis; Infection-Related ANCA-Associated Vasculitis; Overlap Syndrome ANCA-Associated Vasculitis
• Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc. ; AstraZeneca Plc; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Characteristics

3. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Trends And Strategies

4. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Growth Rate Analysis
• 5.4. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Total Addressable Market (TAM)

6. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Segmentation

• 6.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulomatosis With Polyangiitis (GPA Or Wegener's)
• Microscopic Polyangiitis (MPA)
• Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss)
• Other Types
• 6.2. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Corticosteroids
• Biologics
• Other Treatments
• 6.3. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Biopsy
• Imaging
• Other Diagnosis
• 6.4. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Granulomatosis With Polyangiitis (GPA Or Wegener's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Limited Granulomatosis With Polyangiitis
• Severe Granulomatosis With Polyangiitis
• Refractory Granulomatosis With Polyangiitis
• 6.5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Microscopic Polyangiitis (MPA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Renal Microscopic Polyangiitis
• Pulmonary Microscopic Polyangiitis
• Neurological Microscopic Polyangiitis
• 6.6. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiac Eosinophilic Granulomatosis With Polyangiitis
• Pulmonary Eosinophilic Granulomatosis With Polyangiitis
• Neurological Eosinophilic Granulomatosis With Polyangiitis
• 6.7. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug-Induced ANCA-Associated Vasculitis
• Infection-Related ANCA-Associated Vasculitis
• Overlap Syndrome ANCA-Associated Vasculitis

7. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Regional And Country Analysis

• 7.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 8.1. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 9.1. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 9.2. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 10.1. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 11.1. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 11.2. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 12.1. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 13.1. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 14.1. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 14.2. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 15.1. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 15.2. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 16.1. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 17.1. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 18.1. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 19.1. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 20.1. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 21.1. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 21.2. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 22.1. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 23.1. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 23.2. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 24.1. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 24.2. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 25.1. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 25.2. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 26.1. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 26.2. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 27.1. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 28.1. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 28.2. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 29.1. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 29.2. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Landscape And Company Profiles

• 30.1. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Landscape
• 30.2. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Fresenius Medical Care (FMS)
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Otsuka Holdings Co. Ltd.
• 31.5. Biogen Inc.
• 31.6. Quest Diagnostics Inc
• 31.7. Csl Behring AG
• 31.8. ARUP Laboratories
• 31.9. Sebia Inc.
• 31.10. Exagen Inc.
• 31.11. Argenx SE
• 31.12. Arkana Laboratories
• 31.13. Alentis Therapeutics AG
• 31.14. Hansa Biopharma AB
• 31.15. InflaRx NV

32. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

34. Recent Developments In The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

35. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market High Potential Countries, Segments and Strategies

• 35.1 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34761_Antineutrophil_Cytoplasmic_Antibody_ANCA_Associated_Vasculitis_GMR_2025